Agendia Appoints New Chief Financial Officer

Huntington Beach, California, and Amsterdam (ots/PRNewswire)
-- Agendia, a world leader in molecular cancer diagnostics, today
announced the appointment of Kurt Schmidt, CPA, MBA, as the company's
new Chief Financial Officer.

"Kurt is an exceptional addition to our team and an invaluable
asset," said Bernhard Sixt, Ph.D., President and Chief Executive
Officer. "With his extensive financial management experience in the
high tech and healthcare industries, he will be instrumental in
driving Agendia's next phase of growth."

Mr. Schmidt succeeds former Chief Financial Officer, John de Die,
who has been an exemplary guide for Agendia during his tenure. Mr.
Schmidt brings more than 25 years of financial, operational and
entrepreneurial management experience, primarily in the high tech and
healthcare industries in the U.S. and Europe. Most recently, he was a
principal at a consulting firm he founded in 2002, providing
high-level interim financial management and M&A services. Prior to
that, Mr. Schmidt served as Operations Director at B2eMarkets, a
supply chain technology company, and Director of Finance & Operations
at LA Gear Europe. Mr. Schmidt started his career at Cardinal Health,
Inc. in corporate finance.

"I am delighted to join Agendia during this exciting time and
help prepare the company for our next financing round. I look forward
to our first investor meetings next week during the JP Morgan
Healthcare Conference in San Francisco," commented Kurt Schmidt,
Chief Financial Officer.

About Agendia

Agendia is at the forefront of the personalized medicine
revolution, striving to bring more effective, individualized
treatments within reach of patients. Building on a cutting edge
genomics platform for tumor gene expression profiling, the company's
tests aim to help physicians more accurately tailor cancer
treatments. The company markets four products, with several new
genomic tests under development. In addition, Agendia collaborates
with pharmaceutical companies to develop highly effective
personalized drugs in the area of oncology. Agendia was awarded the
2008 North American Oncology Clinical Diagnostics Healthcare
Innovation Award by Frost & Sullivan. Agendia is based in Huntington
Beach, California, and in Amsterdam, The Netherlands. For more
information please visit http://www.agendia.com.

ots Originaltext: Agendia B.V.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
MEDIA CONTACTS: Hans Herklots, Head of Corporate Communications,
Agendia, +31-20-462-1557 Office, +31-620-083-509 Mobile,
hans.herklots@agendia.com; Valerie Delva, Account Executive, Ricochet
Public Relations, +1-212-679-3300 x131 Office, +1-917-975-3191
Mobile, vdelva@ricochetpr.com